11,237 Shares in Medtronic PLC $MDT Acquired by Chesley Taft & Associates LLC

Chesley Taft & Associates LLC purchased a new position in Medtronic PLC (NYSE:MDT) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 11,237 shares of the medical technology company’s stock, valued at approximately $1,070,000.

A number of other hedge funds also recently made changes to their positions in the company. Wynn Capital LLC boosted its stake in shares of Medtronic by 2.4% in the third quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock valued at $442,000 after purchasing an additional 110 shares during the period. Cape Investment Advisory Inc. lifted its holdings in Medtronic by 3.2% in the 2nd quarter. Cape Investment Advisory Inc. now owns 3,605 shares of the medical technology company’s stock worth $314,000 after buying an additional 113 shares in the last quarter. Gilbert & Cook Inc. lifted its holdings in Medtronic by 1.9% in the 2nd quarter. Gilbert & Cook Inc. now owns 6,103 shares of the medical technology company’s stock worth $532,000 after buying an additional 114 shares in the last quarter. Red Spruce Capital LLC boosted its position in Medtronic by 0.5% in the 2nd quarter. Red Spruce Capital LLC now owns 23,707 shares of the medical technology company’s stock valued at $2,067,000 after buying an additional 118 shares during the last quarter. Finally, Certior Financial Group LLC grew its stake in shares of Medtronic by 3.7% during the first quarter. Certior Financial Group LLC now owns 3,450 shares of the medical technology company’s stock valued at $310,000 after acquiring an additional 122 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

MDT has been the topic of several recent analyst reports. Truist Financial cut their price target on Medtronic from $110.00 to $107.00 and set a “hold” rating on the stock in a research note on Thursday. Stifel Nicolaus lifted their price objective on Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a report on Thursday, October 9th. Citigroup increased their target price on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Morgan Stanley raised their price target on shares of Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. Finally, The Goldman Sachs Group set a $111.00 price target on shares of Medtronic and gave the company a “neutral” rating in a report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $109.94.

Medtronic Price Performance

Shares of NYSE MDT opened at $98.54 on Friday. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $126.33 billion, a price-to-earnings ratio of 26.56, a price-to-earnings-growth ratio of 2.59 and a beta of 0.71. Medtronic PLC has a twelve month low of $79.29 and a twelve month high of $106.33. The business has a 50 day simple moving average of $97.32 and a 200-day simple moving average of $93.25.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same period last year, the business posted $1.26 earnings per share. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s dividend payout ratio is currently 76.55%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.